MACK News and Press, Merrimack Pharmaceuticals Inc. From 08/04/22

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its second quarter 2022 financial results for the period ended June 30, 2022. “We are pleased to report continued reductions in operating expenses as we...

Gainers: Applied DNA Sciences ( APDN ) +93% . Alnylam Pharmaceuticals ALNY +55% . Poseida Therapeutics PSTX +47% . NeuroOne Medical Technologies ( NMTC ) +31% . Sonoma Pharmaceuticals ( SNOA ) +21% . Losers: BridgeBio Pharma B...

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] announced that Ipsen, SA (“Ipsen”) has issued a press release today reporting its primary analysis of the results of its Phase 3 trial of Onivyde® (irinotecan l...

Ipsen's ( OTCPK:IPSEY ) ( OTCPK:IPSEF ) pancreatic cancer drug Onivyde did not meet the main goal of overall survival (OS) versus Novartis' ( NVS ) Hycamtin (topotecan) in a phase 3 trial in patients with small cell lung cancer (SCLC), who have progressed on or afte...

Merrimack Pharmaceuticals press release (NASDAQ:MACK): Q1 GAAP EPS of -$0.01. “During the first quarter of 2022 we continued to see reductions in our operating expenses and were able to close the sale of an additional preclinical asset” said Gary Crocker, Chairman of Merrim...

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) [(“Merrimack” or the “Company”)] today announced its first quarter 2022 financial results for the period ended March 31, 2022. “During the first quarter of 2022 we continued to see reductions in our op...

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2021 financial results for the period ended December 31, 2021. “During 2021 we have continued to reduce our operating expenses and remain fo...

The recent market pullback was arguably overdue and is already making stocks attractive for longer-term investors. Insiders are giving excellent industry signals to act on and numerous specific stocks to consider. Take your pick of insider-approved energy, bank, income, infrastruc...

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its third quarter 2021 financial results for the period ended September 30, 2021. “Both Ipsen Pharmaceuticals and Elevation Oncology publicly announced up...

Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) (“Merrimack” or the “Company”) today announced its second quarter 2021 financial results for the period ended June 30, 2021. “We are pleased to report continued reductions in our operating expenses as w...